Humanoids are moving from research labs into real industries — and capital is finally catching up.
Updated
January 8, 2026 6:31 PM
A face of a humanoid robot, side view on black background. PHOTO: UNSPLASH
Humanoid robots are shifting from sci-fi speculation to engineering reality, and the pace of progress is prompting investors to reassess how the next decade of physical automation will unfold. ALM Ventures has launched a new US$100 million early-stage fund aimed squarely at this moment—one where advances in robot control, embodied AI and spatial intelligence are beginning to converge into something commercially meaningful.
ALM Ventures Fund I, is designed for the earliest stages of company formation, targeting seed and pre-seed teams building the foundations of humanoid deployment. It’s a concentrated fund that seeks to take early ownership in a sector that many now consider the next major technological frontier.
For Founder and General Partner Modar Alaoui, the timing is not accidental. “After years of research, humanoids are finally entering a phase where performance, reliability and cost are converging toward commercial viability”, he said. “What the category needs now is focused capital and deep technical diligence to turn prototypes into scalable, enduring companies”.
That framing captures a shift happening across robotics: the field is moving out of the lab and into early commercial readiness. Improvements in perception systems, model-based reasoning and motion control are accelerating the transition. Advances in simulation are also lowering the complexity and cost of integrating humanoid platforms into real environments. As these systems become more capable, the gap between research prototypes and market-ready products is narrowing.
ALM Ventures is positioning itself at this inflection point. Fund I’s thesis centers on the core technologies required to scale humanoids safely and economically. This includes next-generation robot platforms, spatial reasoning engines, embodied intelligence models, world-modeling systems and the infrastructure needed for early deployment. Rather than chasing every robotics trend, the fund is concentrating on the essential layers that will determine whether humanoids can work reliably outside controlled settings.
The firm isn’t starting from zero. During the fund’s formation, ALM Ventures made ten early investments that directly align with its investment focus. The portfolio includes companies building at different layers of the humanoid stack, such as Sanctuary AI, Weave Robotics, Emancro, High Torque Robotics, MicroFactory, Mbodi, Adamo, Haptica Robotics, UMA and O-ID. The list reflects a broad but intentional spread, from hardware to intelligence to manufacturing approaches, all oriented toward enabling scalable physical AI.
Beyond capital, ALM Ventures has been shaping the ecosystem through its global Humanoids Summit series in Silicon Valley, London and Tokyo. The series gives the firm early visibility into emerging technologies, pre-incorporation teams and the senior leaders steering the global robotics landscape. That vantage point has helped the firm identify where commercialization is truly taking root and where bottlenecks still exist.
The rise of humanoids is often compared to the early days of self-driving cars: a long arc of research suddenly meeting an acceleration point. What separates this moment is that advances in embodied AI and spatial intelligence are giving robots a more intuitive understanding of the physical world, making them easier to deploy, teach and scale. ALM Ventures’ Fund I is an attempt to capture that transition while shaping the companies that could define the next technological era.
With US$100 million dedicated to the earliest builders in the space, ALM Ventures is signaling its belief that humanoids are not just another robotics cycle—they may be the next major platform shift in AI.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.